Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLAR: Cobomarsen vs vorinostat in cutaneous T‑cell lymphoma (mycosis fungoides)
2018-000727-13Phase 2Terminated
- Sponsor
- Viridian Therapeutics
- Start
- Jul 2018
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cobomarsen in cutaneous T-cell lymphoma (CTCL) and mycosis fungoides (MF) (2 arms), sponsored by Viridian Therapeutics. Primary endpoint: Primary efficacy evaluation. Started Jul 2018; status: terminated.
02
Drugs
cobomarsen
03
Conditions
cutaneous T-cell lymphoma (CTCL)mycosis fungoides (MF)
Beyond the preview
Go deeper on 2018-000727-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000727-13.